Centres d'excellences Laboratoires d'excellence

Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du cancer

Lipstic

Keywords: Cancer ; inflammation ; traitement ; prévention; lipoprotéines; cible thérapeutiques; vectorisation

Summary

The LipSTIC LabEx consortium was created in 2012 and stands for Lipoproteins and health: prevention and Treatment of Inflammatory diseases and Cancer. The LipSTIC project is based on the disruptive concept that takes advantage of lipoprotein carrier properties to prevent, diagnose, treat and monitor non-vascular inflammatory diseases and cancer.

 

Since 2012, the LipSTIC has contributed to strengthen scientific originality and excellence at the interface of major research areas developed in the BFC region. It is organized in 5 working packages; 1)Transport and vectorization of bioactive molecules; 2)Lipids and inflammation in the initiation and progression of cancer, as well as in immunotherapy; 3)lipids and bacterial endotoxins in inflammatory diseases; 4)Scientific and therapeutic knowledge and innovations for health, 5)Valorization and regulation of innovative drugs.

 

The LipSTIC participates in the creation of new teaching programs: international Master’s degree dedicated to innovative strategies for imaging and nanovectorization and the graduate school INTHERAPI.

 

A major achievement is the transfer of knowledge to valorization with 22 patent registrations, 2 business units (Endoquant®, TASTE-EFFI®) and 2 startup creation (MED’INN Pharma®, EKTAH®). Transfer of knowledge to the public is a priority (cultural events, 4 children’s books) but also to the scientists and health professionals.

 

The LipSTIC has significantly boosts research impact, notably through funding leverage. For example, the licensing of a LipSTIC patent describing a biomarker associated with the risk to develop Age-Related Macular Degeneration, coupled with the establishment of an operational agreement with the startup RetiNov in 2022. Subsequently, the LipSTIC teams secured two additional sources of funding: €50k from INRAE to streamline and industrialize the biomarker assay, and €716k from the ANR BIOMAC to validate its prognostic value and identify the pathological thresholds across European cohorts.

 

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

General informations

Acronym: Lipstic
Reference Number: 11-LABX-0021
Project Region: Bourgogne-Franche-Comté
Discipline: 5 - Bio Med
PIA investment: 8,376,238 €
Start date: February 2012
End date: December 2024

Project coordination : Philippe SAAS
Email: philippe.saas@efs.sante.fr

Consortium du projet

Etablissement coordinateur : Comue Université Bourgogne Franche Comté
Partenaire(s) : Université de Dijon Bourgogne, INSERM Délégation Est, Institut Agro Dijon, Centre de lutte contre le cancer Georges Francois Leclerc, Etablissement Français du Sang Bourgogne Franche-Comté (Sens), INRAE Centre Bourgogne-Franche-Comté, INSERM Délégation Occitanie Méditerranée, Ecole Pratique des Hautes Etudes, CHU de Besançon, CHRU de Dijon, NEXIDIA, Université de Franche Comté

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter